Serum biomarkers ID early pancreatic cancers

This article originally appeared here.
Share this content:
Serum Biomarkers Identify Early Pancreatic Cancers
Serum Biomarkers Identify Early Pancreatic Cancers

(HealthDay News) -- The DNA of two genes is frequently altered in patients with early-stage pancreatic cancer, modifications that can be accurately detected in cancer cells and serum, according to a study published online Oct. 2 in Clinical Cancer Research.

Joo Mi Yi, Ph.D., from the Dongnam Institute of Radiological and Medical Sciences in Busan, South Korea, and colleagues performed a genome-wide pharmacologic transcriptome analysis to identify cancer-specific alterations in DNA methylation in pancreatic cancers.

The researchers found that the BNC1 and ADAMTS1 genes were frequently methylated in 143 pancreatic cancers, with a frequency up to 100 percent for pancreatic intraepithelial neoplasia and 97 percent for stage I invasive cancers. These alterations could also be detected in serum from 42 patients with pancreatic cancer using nanoparticle-enabled methylation-on-beads technology. Using both markers, the overall sensitivity was 81 percent and overall specificity was 85 percent for serum testing.

"Promoter DNA methylation of BNC1 and ADAMTS1 are potential biomarkers to detect early-stage pancreatic cancers," Yi and colleagues conclude.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs